Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued ...

Investigators suggest LDL targets typically reserved for secondary prevention are best in high-risk patients with diabetes.

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial. The higher of two doses of brepocitinib improved ...

FDA grants Orphan Drug Designation to SignaBlok's first-in-class, new mechanism-based TREM-1 peptide inhibitor to treat ...

The study covers the period of 2015-2019, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of covalent BTK inhibitors with fewer adverse events in mantle cell lymphoma.

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will ...

Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.

Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurologic diseases, today announced that Tien Dam, MD, Chief Medical Officer, will ...